Teleflex has officially completed its acquisition of Biotronik’s vascular intervention business, reinforcing its strategic focus on expanding its role in the global peripheral and coronary intervention markets. First announced in February 2025, the deal was valued at $895 million (€760 million) and is expected to deliver significant clinical and commercial synergies across Teleflex’s cardiovascular portfolio.
Biotronik’s vascular product range includes drug-coated balloon catheters, the Papyrus-covered coronary stent designed for acute coronary artery perforations, and a drug-eluting stent—products widely used in catheterization labs and interventional radiology suites. These additions will now complement Teleflex’s existing offerings across vascular and interventional access, surgical, anesthesia, cardiac care, and other critical therapeutic areas.
A central element of the acquisition is the opportunity to scale Teleflex’s Freesolve program. Freesolve is a sirolimus-eluting resorbable metallic scaffold, and with the acquisition now finalized, Teleflex plans to invest in expanding its clinical trial activity, including initiating a U.S.-based study. This aligns with broader efforts to deliver next-generation vascular technologies that could reshape patient care strategies in the cath lab.
“We are pleased to announce the completion of the acquisition of substantially all of the vascular intervention business of Biotronik earlier than expected,” said Liam Kelly, chairman, president and CEO of Teleflex. “The acquisition will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies and improve patient care.”
This move is the latest in a series of actions Teleflex has taken to grow its influence in critical care and vascular markets. In April, the company received expanded FDA 510(k) clearance for its QuikClot Control+ Hemostatic Device, widening its use to include all grades of internal and external bleeding. Earlier in the year, Teleflex secured a contract with Vizient to supply its venous and arterial access catheters.
Meanwhile, Biotronik has pursued its own strategic alignments, including a February partnership with Egg Medical to distribute EggNest radiation protection systems in the U.S. These systems aim to reduce radiation exposure by up to 99% in fluoroscopy procedures.
The finalized deal with Biotronik positions Teleflex to further its investment in innovation while strengthening its market share in interventional cardiovascular care.
Click here for the original news story.